AstraZeneca PLC - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Detailed information on AstraZeneca PLC required for business and competitor intelligence needs
A study of the major internal and external factors affecting AstraZeneca PLC in the form of a SWOT analysis
An in-depth view of the business model of AstraZeneca PLC including a breakdown and examination of key business segments
Intelligence on AstraZeneca PLC’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
News about AstraZeneca PLC, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
AstraZeneca (or 'the company'), a UK-based global biopharmaceutical company, is engaged in developing, manufacturing and marketing prescription pharmaceuticals in several therapeutic areas. The company primarily operates in the Americas, Europe and Asia. It is headquartered in London, the UK, and employed about 57,500 people as on December 31, 2014. The company recorded revenues of $26,095 million during the financial year ended December 2014 (FY2014), an increase of 1.5% over FY2013. The operating profit of the company was $2,137 million in FY2014, a decrease of 42.4% compared with FY2013. The net profit of the company was $1,233 million in FY2014, a decrease of 51.8% compared with FY2013.
Reasons to Purchase:
Gain understanding of AstraZeneca PLC and the factors that influence its strategies
Track strategic initiatives of the company and latest corporate news and actions
Assess AstraZeneca PLC as a prospective partner, vendor or supplier
Support sales activities by understanding your customers' businesses better
Stay up to date on AstraZeneca PLC’s business structure, strategy and prospects